Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + Sintilimab + TACE in Unresectable Hepatocellular Carcinoma
ChiCTR2100050505Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and sintilimab in hepatocellular carcinoma (HCC), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100050505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050505.